お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
966168

樹状細胞がんワクチン免疫療法の世界市場 - 投与量・価格・臨床試験の考察

Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026

出版日: | 発行: KuicK Research | ページ情報: 英文 222 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

樹状細胞がんワクチン免疫療法の世界市場 - 投与量・価格・臨床試験の考察
出版日: 2020年10月19日
発行: KuicK Research
ページ情報: 英文 222 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

過去数年間の医学研究における重要な進歩によって、がん細胞に対する体の免疫系を利用する、新しい扉の開放が可能になりました。がん治療の歴史の中で初めて、研究者は樹状細胞を組み込んだ治療法を発見しました。樹状細胞ワクチン免疫療法のがん治療の導入は、がん患者の樹状細胞治療に関連する機会が膨大で、克服しなければならない複数の科学的・医学的な壁を作る原因になっています。

当レポートでは、世界の樹状細胞がんワクチン免疫療法市場について調査分析し、臨床試験、上市製品、将来の製品、地域別の見通し、臨床パイプライン、主要企業などについて、体系的な情報を提供しています。

目次

第1章 樹状細胞がんワクチンのイントロダクション

  • 樹状細胞がんワクチンの歴史的発展
  • 樹状細胞ワクチン:がん免疫療法の新時代

第2章 免疫系・がん治療における樹状細胞の関連性

  • 樹状細胞:人間の免疫系に不可欠な部分
  • 樹状細胞性免疫のがんに対する影響

第3章 樹状細胞がんワクチン:作用機序

  • 樹状細胞ワクチンの製造
  • がん細胞に対する樹状細胞ワクチンの機序

第4章 併用療法における樹状細胞がんワクチン

  • 放射線治療
  • モノクローナル抗体

第5章 樹状細胞免疫療法市場を前進させる研究・技術協力

第6章 世界の樹状細胞がんワクチン免疫療法における現在の市場概要

第7章 樹状細胞がんワクチン免疫療法市場における地域別の見通し

  • 北米
  • インド
  • 韓国
  • 日本

第8章 世界の樹状細胞がんワクチン免疫療法における臨床試験の情勢

  • フェーズ別
  • 患者セグメント別
  • 企業別
  • 国別
  • がん別

第9章 樹状細胞がんワクチン免疫療法:投与量・有効性・価格の考察

  • Provenge
  • Apceden(Apceden-L、Apceden-O、Apceden-C、Apceden-P)
  • CreaVax RCC

第10章 前立腺がんに対するProvengeとその他の治療薬の比較評価

  • Provenge vs. Jevtana
    • 臨床効果
    • 治療過程・投与量
    • 治療価格分析
  • Provenge vs. Zytiga
    • 臨床効果
    • 治療過程と投与量
    • 治療価格分析

第11章 世界の樹状細胞ワクチン免疫療法における臨床パイプライン:企業別、適応症別、フェーズ別

  • 未確認
  • 研究
  • 前臨床
  • フェーズ0
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズII/III
  • フェーズIII

第12章 上市済みの樹状細胞ワクチン免疫療法における臨床的考察

  • CreaVax
  • Sipuleucel-T(Provenge)
  • 樹状細胞活性化サイトカイン誘導キラー細胞 - ShanghaiJia Fu Medical

第13章 さまざまながんにおける樹状細胞ワクチンの有望な将来

  • III期黒色腫における樹状細胞ワクチン
  • 急性骨髄性白血病における樹状細胞ワクチン
  • 脳腫瘍における樹状細胞ワクチン

第14章 世界の樹状細胞がんワクチンの市場力学

  • 有利な市場パラメーター
  • 市場成長の課題

第15章 世界の樹状細胞がんワクチン市場の将来見通し

  • 市場の将来の過程
  • 樹状細胞がんワクチンの技術的進歩
  • 樹状細胞癌ワクチンの標的患者ベースの可用性

第16章 競合情勢

  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • Bellicum Pharmaceuticals
  • Creagene
  • DanDrit Biotech
  • DCPrime
  • Dendreon Corporation
  • Elios Therapeutics
  • ImmunoCellular Therapeutics
  • Immunicum
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • Glaxo Smith Kline
  • ImmunoCellular Therapeutics
  • SOTIO
  • Tella Incorporation
  • Theravectys
  • Vaxil BioTherapeutics
図表

List of Figures

  • Figure 1-1: Milestones in the History of Dendritic Cell Cancer Vaccine Development
  • Figure 2-1: Dendritic Cell in Human Immune System
  • Figure 2-2: Effects of Tumor Cell in Dendritic Cell Dysfunction Leading to Tumor Progression
  • Figure 3-1: Process of Harvesting Dendritic Cell to Develop Vaccines
  • Figure 3-2: General Mechanism of Action of Dendritic Cell Vaccine
  • Figure 6-1: Global - Scope of Dendritic Cell Cancer Therapy Market by Ongoing Researches
  • Figure 6-2: Global - Scope of Dendritic Cell Cancer Therapy Market by Approved Advanced Therapies
  • Figure 6-3: Global - Scope of Dendritic Cell Vaccine Cancer Therapy Market by Later Phase Clinical Trials
  • Figure 6-4: Global - Number of Advanced Cancer Therapy Research Studies Funded by Non-Profit Organization
  • Figure 7-1: Global - Rocapuldencel-T Market Opportunity Analysis by Epidemiology of Renal Cell Carcinoma (Number of patients), 2020
  • Figure 7-2: India - Average Lung Cancer Prevalence per Year
  • Figure 7-3: India - Lung Cancer Prevalence by Stage (%), 2018
  • Figure 7-4: India - Apceden Market Opportunity by Epidemiology of Lung Cancer (Number of Patients), 2014-2020
  • Figure 7-5: India - Apceden Market Opportunity by Epidemiology of Ovarian Cancer (Number of Patients), 2014-2020
  • Figure 7-6: India - Apceden Market Opportunity by Epidemiology of Colorectal Cancer (Number of Patients), 2014-2020
  • Figure 7-7: India - Apceden Market Opportunity by Epidemiology of Prostate Cancer (Number of Patients), 2014-2020
  • Figure 7-8: South Korea - Renal Cell Carcinoma Population by Stage of Cancer, (%), 2018
  • Figure 7-9: South Korea - CreaVax RCC Market Opportunity by Renal Cancer Epidemiology (Number of Patients), 2014-2020
  • Figure 7-10: South Korea - Renal Cell Carcinoma Prevalence in Male Population by Number, 2014-2020
  • Figure 7-11: South Korea - Renal Cell Carcinoma Prevalence in Female Population by Number, 2014-2018
  • Figure 7-12: South Korea - Renal Cancer Prevalence by Gender, 2020
  • Figure 7-13: Japan - Epidemiology of Cancer by Gender (%), 2020
  • Figure 7-14: Japan - Epidemiology of Cancer (Number of Patients), 2020
  • Figure 7-15: Japan - Vaccell Market Opportunity by Epidemiology of Pancreatic Cancer by Gender (%), 2020
  • Figure 7-16: Japan - Vaccell market Opportunity by Epidemiology of Pancreatic Cancer (Number of Patients), 2020
  • Figure 7-17: Japan - Vaccell Market Opportunity by Epidemiology of Gall Bladder & Biliary Cancer by Gender (%), 2020
  • Figure 7-18: Japan - Vaccell Market Opprtunity by Epidemiology of Gall Bladder & Biliary Cancer (Number of Patients), 2018
  • Figure 7-19: Japan - Vaccell Potential Patient Base by New Incidences, 2020
  • Figure 8-1: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Phase (%), 2020 till 2026
  • Figure 8-2: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Phase (Number), 2020 till 2026
  • Figure 8-3: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Patient Segment (Number), 2020 till 2026
  • Figure 8-4: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Patient Segment (Number), 2020 till 2026
  • Figure 8-5: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Country (Number), 2020 till 2026
  • Figure 8-6: Global - Dendritic Cell Cancer Vaccine Immunotherapy Clinical Pipeline by Country (Number), 2020 till 2026
  • Figure 9-1: Provenge - Patent Issue & Expiration Year
  • Figure 9-2: Provenge: Efficacy on the Basis of Clinical Trials
  • Figure 9-3: Provenge - Number of Autologous CD54+ Activated Cells (Million)
  • Figure 9-4: Provenge - Dosage Administration (Minutes)
  • Figure 9-5: Provenge - Average Duration of Therapy
  • Figure 9-6: Provenge - Duration of Single Treatment Cycle & Full Treatment (Weeks), October'2020
  • Figure 9-7: Provenge - Price for 250 ml Supply & Price per ml of Intravenous Suspension (US$), October'2020
  • Figure 9-8: Provenge - Cost of Single Treatment Cycle & Cost of Full Treatment (US$), October'2020
  • Figure 9-9: Provenge - Company's Expenditure in Drug Development & Therapy Market Value (US$ Billion)
  • Figure 9-10: Apceden - Median Progression-Free Survival in Patients with Solid Tumors (Number of Months)
  • Figure 9-11: Apceden - Median Progression Free Survival in Patients with Progressive Solid Tumors (Number of Months)
  • Figure 9-12: Apceden v/s Provenge - Adverse Side Effects (%), 2018
  • Figure 9-13: Apceden - Availability of Vial & Vials Required in Apceden Therapy
  • Figure 9-14: Apceden - Intervals Between Multiple Doses of Treatment
  • Figure 9-15: Apceden - Cost of Single Vaccine, 6 Vaccines & 12 Vaccines (US$/INR), October'2020
  • Figure 9-16: CreaVax RCC - Approval Analysis by Phase (Year)
  • Figure 9-17: CreaVax RCC - Treatment Course Duration (Weeks)
  • Figure 9-18: CreaVax RCC - Vial Composition Analysis (mL/Dose & Number of Cells/Dose)
  • Figure 9-19: South Korea - CreaVax RCC Patent Cost (US$)
  • Figure 9-20: South Korea - Pharmaceutical Compositions comprising Dendritic Cell Patent Cost (US$)
  • Figure 10-1: Provenge v/s Jevtana - Median Progression Free Survival (Months)
  • Figure 10-2: Provenge v/s Jevtana - Overall Survival (Months)
  • Figure 10-3: Provenge v/s Jevtana - Discontinuation of Treatment in Patients due to Adverse Effects (%)
  • Figure 10-4: Provenge v/s Jevtana - Average Treatment Cycles in Complete Therapy (By Number)
  • Figure 10-5: Provenge v/s Jevtana - Price Analysis (US$/Unit), 2020
  • Figure 10-6: Provenge v/s Jevtana - Price Analysis (US$/Infusion), 2018
  • Figure 10-7: Provenge v/s Jevtana - Average Treatment Cost Analysis (US$), 2020
  • Figure 10-8: Provenge v/s Zytiga - Median Progression Free Survival (Months)
  • Figure 10-9: Provenge v/s Zytiga - Therapy Cost Analysis (US$), 2020
  • Figure 14-1: Factors Favoring Global Dendritic Cell Cancer Vaccine Market
  • Figure 15-1: Future Drivers for Dendritic Cell Immunotherapy Market
  • Figure 15-2: Global - Dendritic Cell Cancer Vaccine Market Opportunity by Prevalence of Cancer (%)
  • Figure 16-1: Argos Therapeutics- Clinical Pipeline
  • Figure 16-2: Bellicum Pharmaceuticals Clinical Pipeline
  • Figure 16-3: DCPrime Clinical Pipeline
  • Figure 16-4: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 16-5: Immunicum Clinical Pipeline
  • Figure 16-6: Medigene Clinical Pipeline
  • Figure 16-7: Northwest Biotherapeutics Clinical Pipeline
  • Figure 16-8: SOTIO Clinical Pipeline
目次

"Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

  • Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
  • Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
  • Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
  • Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
  • Global Dendritic Cell Cancer Vaccine Immunotherapy Market Regional Outlook
  • Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
  • Dosage, Efficacy & Price Insight of Provenge , Apceden & CreaVax

In the past few years, significant breakthroughs in the medical research have led to the opening of novel doors to harness the immune system of the body against the cancer cells. For the very first time in the history of cancer therapeutics , researchers have discovered a cure that incorporates dendritic cells. The introduction of dendritic cell vaccine immunotherapy into the cancer therapeutics has caused several scientific and medical hurdles to overcome as the opportunities linked with dendritic cells treatment for the cancer patients are huge.

Dendritic cell vaccine immunotherapy among all the immunotherapy treatments is considered as the most potent antigen presenting cells for the proliferation of the T-cells. The uniqueness embedded in the treatment have prompted their applications to be involved in majority of the treatments as well as wider-acceptance across the globe. The potential of immune system in fighting cancer cells got recognized three-four decades before. Since then, technological and innovative advancement in scientific knowledge have led to the development of novel ally for the cancer patients, which has now become the only hope for declining the cancer mortality rate.

The opening of novel research frontiers with the understanding of biological mechanisms underlying the human cancer and immune system are estimated to be creating promising trends and opportunities for the researchers, patients, physicians and the stakeholders. In addition, some of the factors that are leading to the exponential growth of the market in terms of revenue and size are increasing cancer cases, awareness about the advantages of the dendritic cell vaccine immunotherapy, technology advancement and many more. The dendritic cell vaccine immunotherapy market is catalyzed by a completely and exciting novel range of disruptive technologies required for the re-definition of cancer therapeutics market. In the next few years, researchers are estimated to bring a shift in the treatment paradigm where temporary respite of the cancer treatment will not be boosted in the cancer therapeutic challenge. In the new world, dendritic cell vaccine immunotherapy is estimated to be conquering all the challenges that were challenging to conquer before the arrival of the therapy.

The dendritic cell vaccine immunotherapy market for the cancer patients is estimated to be driven by major three developments advancement in the technology, groundbreaking mechanism of action of the dendritic cells against the cancer cells and consumerization of health through increased access to the patient data provided by artificial intelligence. Unlike, chemotherapy or radiation therapy with which disadvantages are more than advantages, dendritic cell vaccine immunotherapy is estimated to be bursting that bubble. The clinical successes achieved through the therapy has led to the downfall of the hype generated by the old and traditional therapies and eventually boosted the products that are already in the market for the consumption.

The future of the market is estimated to reveal the durability of the clinical responses as well as there will be a significant improvement with respect to broad spectrum development of the market. The downward pressure on the pricing of the developed drugs is estimated to change the upsetting of the market, leading to a great emphasis on the market expansion and acceptance at an international level. Along with these, the market is also observing major players emerging for the overall development of the market.

As per the analysis for Dendritic cell vaccine immunotherapy market, it is estimated that the arrival of the therapy into the market has ended the long-waiting scenario of a therapy capable of efficiently manipulating the dendritic cells and targeting it against the cancer cells. The global healthcare industry for cancer was in an urgent need of such promising therapy where patients could have increased five-year survival rate, minimum side-effects, better targeting ability of the manipulated cells and many more. The unprecedented market drivers are providing a deep insight of the market with respect to the overall progression and its aim to re-define the overall success meter in cancer market as the therapy is tending to perform with high rate of performance.

Table of Contents

1. Introduction to Dendritic Cell Cancer Vaccine

  • 1.1. Dendritic Cell Cancer Vaccine Historical Development
  • 1.2. Dendritic Cell Vaccines: A New Era for Cancer Immunotherapy

2. Relevance of Dendritic Cells in Immune System & Cancer Therapy

  • 2.1. Dendritic Cell: Integral Part of Human Immune System
  • 2.2. Effects of Cancer on Dendritic Cell Mediated Immunity

3. Dendritic Cell Cancer Vaccines: Mechanism of Action

  • 3.1. Manufacturing of Dendritic Cell Vaccines
  • 3.2. Mechanism of Dendritic Cell Vaccine against Cancer Cells

4. Dendritic Cell Cancer Vaccine In Combination Therapy

  • 4.1. Radiotherapy
  • 4.2. Monoclonal Antibodies

5. Research & Technological Collaborations for Advancing the Dendritic Cell Immunotherapy Market

  • 5.1. UCLA Researchers Re-Defying Research for Dendritic Cell Immunotherapy
  • 5.2. Personalized Dendritic Cell Vaccine Improving the Overall Survival Rate of Glioblastoma Patients
  • 5.3. Cutting-Edge Grant Approval for Dendritic Cell Immunotherapy Market Advancement in UCLA
  • 5.4. Dendritic Cell Cytokines Leading to Increased Clinical Outcome in Case of Different Cancer Types
  • 5.5. Human Telomerase Reverse Transcriptase (hTERT)-Expressing Autologous Dendritic Cells (hTERT-DCs) Efficiency in Case of Acute Myeloid Leukemia
  • 5.6. APAC Biotech Company to Deliver Dendritic Cell Immunotherapy in India
  • 5.7. Nimbus Therapeutics & Celgene to Work Together for Expanding the Applications of Dendritic Cell Therapy
  • 5.8. Specific Dendritic Cell Vaccines ATTAC Study Result for the Treatment of Glioblastoma
  • 5.9. Bristol Myers Squibb & UbiVac Announces Collaboration for Dendritic Cell-Targeted Microvesicle (DPV-001)
  • 5.10. Cancer Research UK & VOLT to Conduct First-in-Human Trial for Dendritic Cell Therapy
  • 5.11. University of California San Diego Research Work for Confirming the Efficacy of Dendritic Cell Cancer Vaccines
  • 5.12. Interleukin-32 Dendritic Cell Therapy Provoking Promising Strategy Treatment
  • 5.13. Elicio Therapeutics & Moffitt to Evaluate the Combinational Outcomes for AMP-CD19 & CD19 CAR-T Cells
  • 5.14. Dendritic Cell Immunotherapy Discovery as Novel Guards for Immune System
  • 5.15. Non-Small Cell Lung Cancer Treatment by Autologous Dendritic Cancer Cell Vaccines
  • 5.16. Dendritic Cell Immunotherapy Preliminary Reports for Solid & Haematological Malignancies

6. Global Dendritic Cell Cancer Vaccine Immunotherapy Current Market Overview

7. Dendritic Cell Cancer Vaccine Immunotherapy Market Regional Outlook

  • 7.1. North America
  • 7.2. India
  • 7.3. South Korea
  • 7.4. Japan

8. Global Dendritic Cell Cancer Vaccine Immunotherapy Clinical Trials Landscape

  • 8.1. By Phase
  • 8.2. By Patient Segment
  • 8.3. By Company
  • 8.4. By Country
  • 8.5. By Cancer

9. Dendritic Cell Cancer Vaccine Immunotherapy - Dosage, Efficacy & Price Insight

  • 9.1. Provenge
  • 9.2. Apceden (Apceden-L, Apceden-O, Apceden-C, Apceden-P)
  • 9.3. CreaVax RCC

10. Comparative Assessment of Provenge v/s other Therapeutics for Prostate Cancer

  • 10.1. Provenge v/s Jevtana
    • 10.1.1. Clinical Efficacy
    • 10.1.2. Treatment Course & Dosage
    • 10.1.3. Therapy Price Analysis
  • 10.2. Provenge v/s Zytiga
    • 10.2.1. Clinical Efficacy
    • 10.2.2. Treatment Course & Dosage
    • 10.2.3. Therapy Price Analysis

11. Global Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase

  • 11.1. Unknown
  • 11.2. Research
  • 11.3. Preclinical
  • 11.4. Phase-0
  • 11.5. Phase-I
  • 11.6. Phase-I/II
  • 11.7. Phase-II
  • 11.8. Phase-II/III
  • 11.9. Phase-III

12. Marketed Dendritic Cell Vaccines Immunotherapy Clinical Insight

  • 12.1. CreaVax
  • 12.2. Sipuleucel-T (Provenge)
  • 12.3. Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

13. Promising Future of Dendritic Cell Vaccines in Various Cancer

  • 13.1. Dendritic Cell Vaccine in Stage-III Melanoma
  • 13.2. Dendritic Cell Vaccine in Acute Myeloid Leukemia
  • 13.3. Dendritic Cell Vaccine in Brain Tumor

14. Global Dendritic Cell Cancer Vaccine Market Dynamics

  • 14.1. Favorable Market Parameters
  • 14.2. Market Growth Challenges

15. Global Dendritic Cell Cancer Vaccine Market Future Outlook

  • 15.1. Future Course for Market
  • 15.2. Dendritic Cell Cancer Vaccine Technical Advancements
  • 15.3. Availability of Target Patient Base for Dendritic Cell Cancer Vaccines

16. Competitive Landscape

  • 16.1. 3M Company
  • 16.2. Activartis
  • 16.3. Argos Therapeutics
  • 16.4. Batavia Bioservices
  • 16.5. Bellicum Pharmaceuticals
  • 16.6. Creagene
  • 16.7. DanDrit Biotech
  • 16.8. DCPrime
  • 16.9. Dendreon Corporation
  • 16.10. Elios Therapeutics
  • 16.11. ImmunoCellular Therapeutics
  • 16.12. Immunicum
  • 16.13. Kiromic
  • 16.14. Medigene
  • 16.15. Merck
  • 16.16. Northwest Biotherapeutics
  • 16.17. Glaxo Smith Kline
  • 16.18. ImmunoCellular Therapeutics
  • 16.19. SOTIO
  • 16.20. Tella Incorporation
  • 16.21. Theravectys
  • 16.22. Vaxil BioTherapeutics
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.